Fertility and pregnancy considerations in patients with glioma: a review of current guidelines and evidence gaps
Clicks: 4
ID: 324788
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.9
/100
4 views
3 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #25 of 43 articles by views in Neuro-Oncology Practice
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Gliomas are among the most common primary CNS tumors in adolescents and young adults (AYAs; ages 15–39 years), and several subtypes are associated with prolonged survival. As a result, fertility preservation and pregnancy management have become increasingly important components of survivorship care; however, current evidence remains scarce. Despite family planning needs, many patients receive limited counselling, and both referral to and access to reproductive specialists remains inconsistent. Glioma‑directed therapies may impair fertility through gonadotoxic chemotherapy, hypothalamic–pituitary dysfunction, or prolonged exposure to targeted agents with poorly defined reproductive effects. Pregnancy after glioma diagnosis introduces additional complexities, including concerns regarding tumor progression, optimal timing of conception, antiseizure medication selection, and obstetric and neonatal risks. Evidence describing the interaction between pregnancy and glioma biology is limited to small retrospective series with heterogeneous imaging practices and minimal molecular characterization. Available data suggest that tumor behavior during pregnancy largely reflects underlying histology, grade, and prior treatment, with progression more frequently reported in higher‑grade disease and transient increases in growth kinetics described in some IDH‑mutant diffuse gliomas. Overall survival does not appear adversely affected by pregnancy. This review synthesizes current guidelines and evidence across fertility preservation, preconception planning, and cancer management during pregnancy, emphasizing multidisciplinary care and highlighting key evidence gaps—particularly regarding targeted therapies, optimal surveillance, and molecularly informed risk stratification—to guide future research and clinical practice.
| Reference Key |
openalex_W7202267583
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Jaime Godoy-Santín, Jan‐Michael Werner, Norbert Galldiks, Lisa Werr, Nicola Farnell, Jay Detsky, Saira Alli, Noor Niyar N Ladhani, Anna S. Berghoff, Mary Jane Lim-Fat |
| Journal | Neuro-Oncology Practice |
| Year | 2026 |
| DOI |
10.1093/nop/npag082
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.